Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
This article was originally published in The Pink Sheet Daily
Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.
You may also be interested in...
Novartis posted solid growth of 9% in Q1 in emerging markets, with China sales up 21%; Lilly reports strong sales in China lifted revenues by 11%.
Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.